Paratek Pharmaceuticals Inc  

(Public, NASDAQ:PRTK)   Watch this stock  
Find more results for NASDAQ:TSPT
+0.30 (1.45%)
After Hours: 20.97 0.00 (0.00%)
Dec 1, 4:52PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 20.11 - 21.03
52 week 15.02 - 39.80
Open 20.77
Vol / Avg. 42,185.00/64,279.00
Mkt cap 347.74M
P/E     -
Div/yield 8.01
EPS -4.04
Shares 17.61M
Beta 0.51
Inst. own 92%
Nov 12, 2015
Q3 2015 Paratek Pharmaceuticals Inc Earnings Call - Webcast
Nov 12, 2015
Q3 2015 Paratek Pharmaceuticals Inc Earnings Release
Nov 3, 2015
Paratek Pharmaceuticals Inc at �EBD BIO Europe- Fall
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -410.76%
Operating margin - -179.59%
EBITD margin - -145.65%
Return on average assets -58.55% -32.06%
Return on average equity -71.93% -
Employees 13 -
CDP Score - -


75 Kneeland St Fl 6
BOSTON, MA 02111-1901
United States - Map
+1-617-2750040 (Phone)
+1-617-2750039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek's two antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). Sarecycline is in Phase III clinical trial stage for the treatment of acne, and omadacycline has completed Phase III clinical trial for treatment of complicated skin and skin structure infection (cSSSI), and Phase II clinical trials for the treatment of ABSSSI and CABP. Sarecycline is a once-daily, tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Officers and directors

Michael F. Bigham CPA Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Evan Loh M.D. President, Chief Medical Officer, Director
Age: 56
Bio & Compensation  - Reuters
Douglas W. Pagan Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
William M. Haskel Senior Vice President, General Counsel, Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Regina D. Paglia Senior Vice President - Human Resources
Bio & Compensation  - Reuters
Stephen Villano M.D. Vice President - Clinical and Medical Affairs
Bio & Compensation  - Reuters
Adam Woodrow Vice President and Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Timothy R. Franson M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard J. Lim Independent Director
Age: 43
Bio & Compensation  - Reuters
Robert Radie Independent Director
Age: 51
Bio & Compensation  - Reuters